Anish Amin

Nov 1, 2024 | hmpgloballearningnetwork.com | Chinmaya Mareddy |Jose Silva |José Silva |Matthew Sackett |Anish Amin

© 2024 HMP Global. All Rights Reserved. Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of EP Lab Digest or HMP Global, their employees, and affiliates. EP LAB DIGEST. 2024;24(11):22-23.

Dec 4, 2023 | onlinelibrary.wiley.com | Bradley P. Knight |Nicolas Clementy |Anish Amin |Ulrika Birgersdotter-Green

1 INTRODUCTION Implantable cardioverter-defibrillator (ICD) therapy is associated with a mortality benefit for patients at risk for sudden cardiac death.1-4 Understanding the costs of ICD therapy involves not only the costs of initial implantation but also the ongoing costs related to standard device follow-up, generator changes for battery depletion, and the management of device-related complications over the life of the patient. Innovations in ICD technology can impact these costs.